| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 03/17/2005 | WO2005023860A2 Modified il-4 mutein receptor antagonists |
| 03/17/2005 | WO2005023859A1 A protein involved in carcinoma |
| 03/17/2005 | WO2005023858A1 Protein complexes associated with app-processing |
| 03/17/2005 | WO2005023856A2 Cyclic nucleotide-specific phosphodiesterases from leishmania and uses thereof |
| 03/17/2005 | WO2005023855A2 K203 gene and protein |
| 03/17/2005 | WO2005023854A2 Modified 6-phosphofructo-1-kinase of the fungus aspergillus niger |
| 03/17/2005 | WO2005023853A1 Protease-resistant seb variant and vaccine containing the same |
| 03/17/2005 | WO2005023852A2 Epilancin 15x lantibiotic |
| 03/17/2005 | WO2005023851A1 Plasminogen/plasmin binding polypeptides and nucleic acids therefore |
| 03/17/2005 | WO2005023850A2 Method for producing inosine and 5'-inosinic acid by fermentation using bacterium belonging to the genus escherichia |
| 03/17/2005 | WO2005023849A2 Antigenic peptides of rabies virus and uses thereof |
| 03/17/2005 | WO2005023848A2 Adenoviral epitopes |
| 03/17/2005 | WO2005023847A1 COMPOSITION FOR PROTECTING PROTEINS DEGRADATION COMPRISING SMALL HEAT SHOCK PROTEINS (sHSPs) AND METHOD OF TWO-DIMENSIONAL GEL ELECTROPHORESIS USING THE sHSPs |
| 03/17/2005 | WO2005023845A2 Cyclic peptides acting as urotensin-ii antagonists |
| 03/17/2005 | WO2005023840A1 Chromatographic separation of therapeutic polypeptides |
| 03/17/2005 | WO2005023839A1 One-step reduction and alkylation of proteins |
| 03/17/2005 | WO2005023837A2 Ebola peptides and immunogenic compositions containing same |
| 03/17/2005 | WO2005023834A2 Peptides and compounds that bind to thrombopoietin receptors |
| 03/17/2005 | WO2005023833A2 Treatment of neurodegenerative diseases |
| 03/17/2005 | WO2005023300A2 Method for treating, preventing and/or diagnosing cancer, related to the use of mal2 polypeptide |
| 03/17/2005 | WO2005023297A1 Composition for the prophylaxis/treatment of hbv infections and hbv-mediated diseases |
| 03/17/2005 | WO2005023296A1 Treatment of rheumatic diseases |
| 03/17/2005 | WO2005023288A1 Treatment of fibrotic disease |
| 03/17/2005 | WO2005023195A2 Treatment of spinal cord injury |
| 03/17/2005 | WO2005023096A2 Methods and compositions for ultrasound imaging of apoptosis |
| 03/17/2005 | WO2004113378A3 Control of lactation and peptides therefore |
| 03/17/2005 | WO2004111078A3 Compounds that modulate the glucagon response and uses thereof |
| 03/17/2005 | WO2004108761A3 Canine ghrh gene, polypeptides and methods of use |
| 03/17/2005 | WO2004101618A3 Progestin-yol002c-cgi-45 receptor-related proteins |
| 03/17/2005 | WO2004096856A3 Secreted protein family |
| 03/17/2005 | WO2004094589A3 Secreted proteins |
| 03/17/2005 | WO2004092194A3 Chimeric polypeptides and their use |
| 03/17/2005 | WO2004090142A8 Plants having modified growth characteristics and method for making the same |
| 03/17/2005 | WO2004090141A8 Method to increase stress tolerance in plants |
| 03/17/2005 | WO2004089376A3 Identification and targeting of consensus sites by which dynorphin exerts its neurotoxic effects enables analgesia without neurotoxicity |
| 03/17/2005 | WO2004087749A3 Nontypeable haemophilus influenzae virulence factors |
| 03/17/2005 | WO2004086052A3 Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b) |
| 03/17/2005 | WO2004084797A3 Type 2 diabetes mellitus-associated gene and utilization of the same |
| 03/17/2005 | WO2004083404A3 Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain |
| 03/17/2005 | WO2004083383A3 Globin variant gene methods and compositions |
| 03/17/2005 | WO2004083243A8 Amylin aggregation inhibitors and use thereof. |
| 03/17/2005 | WO2004082608A9 Ligands for tgf-beta binding proteins and uses thereof |
| 03/17/2005 | WO2004082455A3 Method for detecting alzheimer’s disease and corresponding peptides and detection reagents |
| 03/17/2005 | WO2004076675A3 Glutamate transport modulatory compounds and methods |
| 03/17/2005 | WO2004076619A3 New dengue and west nile viruses proteins and genes coding the foregoing, and their use in vaccinal, therapeutic and diagnostic applications |
| 03/17/2005 | WO2004075843A3 Glycosolated enkephalin agents |
| 03/17/2005 | WO2004074461A3 Production of modified glycoproteins having multiple antennary structures |
| 03/17/2005 | WO2004072605A3 Method for the characterization of proteins, isolated proteins and uses therefore |
| 03/17/2005 | WO2004072098A3 Immunocompromised rodents as dual color tumor models |
| 03/17/2005 | WO2004069165A3 Methods and compositions for the treatment of gastrointestinal disorders |
| 03/17/2005 | WO2004067727A3 Mixing and matching tc proteins for pest control |
| 03/17/2005 | WO2004058815A3 Centrosome-associated protein and applications thereof |
| 03/17/2005 | WO2004056868A3 Nf-hev compositions and methods of use |
| 03/17/2005 | WO2004056862A3 Immunogenic compositions to the cck-b/gastrin receptor and methods for the treatment of tumors |
| 03/17/2005 | WO2004050857A3 Splice variant of human sodium iii channel (hnaiii18) |
| 03/17/2005 | WO2004048529A3 Cell adhesion and extracellular matrix proteins |
| 03/17/2005 | WO2004048403A3 Hepatisis c virus nonstructural protein 4a (ns4a) is an enhancer element |
| 03/17/2005 | WO2004047871A3 Modified naturetic compounds, conjugates, and uses thereof |
| 03/17/2005 | WO2004041851A3 Vaccine |
| 03/17/2005 | WO2004032850A3 Uses of human zven antagonists |
| 03/17/2005 | WO2004029276A9 Nucleic acids encoding a mammalian raptor polypeptide and uses therefor |
| 03/17/2005 | WO2004010767A3 Application of aspen mads-box genes to alter reproduction and development in trees |
| 03/17/2005 | WO2003104429B1 Genes overexpressed by ovarian cancer and their use in developing novel therapeutics |
| 03/17/2005 | WO2003101484A9 Compositions and methods for transepithelial molecular transport |
| 03/17/2005 | WO2003101398A8 Variants of antithrombin iii |
| 03/17/2005 | WO2003060069A3 Compositions and methods relating to hepatic specific genes and proteins |
| 03/17/2005 | WO2003054215A3 Therapeutic protein and nucleic acid |
| 03/17/2005 | WO2003048320A3 Novel motor protein of p. falciparum and methods for its use |
| 03/17/2005 | WO2003016489A8 Porcine leptin protein, antisense and antibody |
| 03/17/2005 | WO2003011898A3 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses |
| 03/17/2005 | WO2002100343A3 N-terminally truncated galectin-3 and antibodies for treating cancer |
| 03/17/2005 | WO2002079227A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 03/17/2005 | WO2002074156A8 Compositions and methods for the therapy and diagnosis of colon cancer |
| 03/17/2005 | US20050060779 Lectin-derived progenitor cell preservation factors and methods of use |
| 03/17/2005 | US20050060776 Expression of biologically active polypeptides in duckweed |
| 03/17/2005 | US20050060774 Arabidopsis thaliana derived frigida gene conferring late flowering |
| 03/17/2005 | US20050060773 Expression vector comprising nucleotide sequences coding gene associated with plant dwarfing (RHT) for use as tool in establishing seedling development in plants |
| 03/17/2005 | US20050060772 Controlling abscission in a transformed plant comprising overexpression of ethylene insensitivity (EIN) gene; tissue engineering and plant storage stability; flower senescence and fruit ripening |
| 03/17/2005 | US20050060770 Antifungal proteins |
| 03/17/2005 | US20050060766 Cloning non-human mammal through nuclear transfer/transplantation; tissue engineering and treatment of cancer, psoriasis, asthma and inflammation |
| 03/17/2005 | US20050060764 Mouse model for bone metabolism |
| 03/17/2005 | US20050060761 Using tetanus toxin/reporter protein fusion as diagnstic tool in detection, monitoring and diagnosis of neurodegenerative disease |
| 03/17/2005 | US20050059816 Novel human protease inhibitor proteins and polynucleotides encoding the same |
| 03/17/2005 | US20050059808 Mixture comprising type I transmembrane protein with immunoglobulin like extracellular domain for use as tool in identifying modulator which control development, differentiation and/or physiology of mammalian immune system |
| 03/17/2005 | US20050059807 Transcriptional modulator for use in the treatment and prevention of cell proliferative, muscular, blood, gastrointestinal and cardiovascular disorders |
| 03/17/2005 | US20050059805 Method for purifying calcium ion-binding protein |
| 03/17/2005 | US20050059804 Porcine alpha2delta-1 calcium channel submit cDNA and soluble secreted alpha2delta-1 subunit polypeptides |
| 03/17/2005 | US20050059803 Oligonucleotide probe for use in detection of phosphatidyl inositol 3 kinase expression; fungicides; antitumor agents |
| 03/17/2005 | US20050059802 chimeric peptide of a peptide wherein the carboxyl terminus of the first portion (comprising a naturally-occurring internal peptide cleavage product) is linked to the amino terminus of the second portion (comprising a T helper cell epitope) |
| 03/17/2005 | US20050059801 Transmembrane receptor/chemokine receptor for use in identifying modulators for treatment of glomerulonephritis, asthma, inflammatory bowel, transplant rejection and inflammation |
| 03/17/2005 | US20050059631 Lowering circulating free fatty acid levels in an individual by administering purified, isolated, or recombinant OBG3 or gOBG3 polypeptide fragment that has significantly greater activity than a full-length OBG3 polypeptide; treatment of hyperlipidemias, atherosclerosis, diabetes, and hypertension |
| 03/17/2005 | US20050059628 Modulation of beta-catenin/TCF-activated transcription |
| 03/17/2005 | US20050059625 Immunostimulatory nucleic acid molecules |
| 03/17/2005 | US20050059623 linking chaperone protein promoters to genetically engineered genes, then heating |
| 03/17/2005 | US20050059620 Promoter driven tissue specific cytotoxic agents and title methods of use |
| 03/17/2005 | US20050059618 Men protein, gst2, rab-rp1, csp, f-box protein lilina/fbl7, abc50, coronin, sec61 alpha, or vhappa1-1, or homologous proteins involved in the regulation of energy homeostasis |
| 03/17/2005 | US20050059605 arylalkyls coupled to glucagon like peptides, growth hormone releasing hormone, vasoactive intestinal peptides, glucose-dependent Insulinotropic peptides, glucagon, neuropeptide Y, peptide YY or gastrin releasing peptides, used for prevention of metabolic disorders |
| 03/17/2005 | US20050059604 A GPCR-like protein for treating glaucoma |
| 03/17/2005 | US20050059602 Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders |
| 03/17/2005 | US20050059601 by administering an exendin peptide analog of given amino acid sequence; treating Type II diabetes, eating disorders, and insulin-resistance syndrome |